Last reviewed · How we verify
NCT07003555
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 trial testing Dual-targeting BCMA-CD19 CAR-T cell infusion in Relapsed or Refractory Multiple Myeloma (RRMM) in 18 participants. Currently enrolling.
25 May 2027
Quick facts
| Lead sponsor | Beijing GoBroad Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 25 May 2025 |
| Primary completion | 25 May 2027 |
| Estimated completion | 25 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Dual-targeting BCMA-CD19 CAR-T cell infusion — full drug profile →
Conditions studied
- Relapsed or Refractory Multiple Myeloma (RRMM) — all drugs for Relapsed or Refractory Multiple Myeloma (RRMM) →
Sponsor
Beijing GoBroad Hospital
Who can join
Adults 18 to 75, any sex, with Relapsed or Refractory Multiple Myeloma (RRMM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - CD19 CAR-T cell therapy. The primary objective is to prospectively evaluate the safety of dual-targeting BCMA and CD19 CAR - T cell therapy for extramedullary infiltration in relapsed/refractory multiple myeloma. The primary endpoints are to assess the type and incidence of dose-limiting toxicity (DLT) within one month after the infusion of BCMA-CD19 CAR-T cells in patients, as well as the incidence and severity of adverse events within one month after the infusion. It is expected that no more than 18 participants will be recruited.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Verify or expand the search:
- PubMed search for NCT07003555
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed or Refractory Multiple Myeloma (RRMM)
Currently open trials in the same condition.
- NCT07003568 — Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration · Phase 1 · recruiting
- NCT06961669 — Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma · NA · recruiting
- NCT06615479 — A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or · Phase 3 · recruiting
- NCT06484829 — Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refracto · Phase 1, PHASE2 · recruiting
Other Beijing GoBroad Hospital trials
Trials by the same sponsor.
- NCT07520357 — A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinom · Phase 2 · not yet recruiting
- NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
- NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07179484 — To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07003555 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing GoBroad Hospital
- Last refreshed: 26 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07003555.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing